Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

Original Article

S. Loibl, Y.H. Park, Z. Shao, C.-S. Huang, C. Barrios, J. Abraham, A. Prat, N. Niikura, S.-A. Im, W. Li, H. Li, Y. Wang, H. Yao, S.-B. Kim, C. Geng, W.R. Pantigoso, F.J.R. Godinez, C. Song, Y.C. Chang, A. Antoniazzi, S.-C. Chen, Z. Li, Z. Nowecki, J. Lim, E. Mathias, Y. Sato, W. Lu, H. Abdel-Monem, M. Untch, and C.E.G. Jr., Jr.

N Engl J Med 2026;394:845-857

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
02/25/2026
Course expires: 
02/26/2028

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Please sign in or create an account to take the course.